摘要
生物医学成像是癌症等疾病诊断和治疗的一个重要工具。可能确实生物医学成像方法应用促进了医学的进一步发展。生物医学成像方法的灵敏度和分辨率可以通过造影剂提高。此外, 产生了一个理想化的想法:造影剂是否可以用作药物。因此,一剂既可以用于疾病的诊断也能用于疾病的治疗(即,治疗诊断)。这将简化医疗疾病的治疗,也将有利于患者。混合(Ln1xLn2yO3 x + y = 2)或纯(Ln2O3)氧化镧系(Ln)纳米颗粒(Ln = Eu、Gd、 Dy、Tb、 Ho和Er)是潜在的多模式成像剂和癌症治疗剂。镧系元素有各种磁性和光学特性,分别用于磁共振成像(MRI)和荧光成像(FI)。他们也发射非常细小的x射线,用于x射线计算机断层扫描(CT)。另外在稳定的放射性核素中,钆-157(157 gd)有着最高的热中子俘获截面,用于钆中子俘获治疗(GdNCT)。因此,混合或纯镧系元素氧化物纳米粒子(即可以用于多模式成像方法,例如MRI-CT MRI-FI CT-FI,MRICT - FI)和癌症治疗(即GdNCT)。因为混合或纯镧系元素氧化物纳米颗粒是单相和固态,它们可以很容易地合成,紧凑和稳固,这有益于其在生物医学上的应用。本文综述镧系元素的物理性质、合成、混合材料的特点、多模式成像、癌症治疗,并讨论了纯氧化镧纳米颗粒在癌症治疗的应用。
关键词: 癌症治疗,荧光成像-计算机断层扫描,钆中子俘获治疗,混合或纯镧系元素氧化物纳米颗粒,多模式成像,磁共振成像-计算机断层扫描,磁共振成像-计算机断层扫描-荧光成像,磁共振成像-荧光成像
Current Medicinal Chemistry
Title:Multi-Modal Imaging and Cancer Therapy Using Lanthanide Oxide Nanoparticles: Current Status and Perspectives
Volume: 22 Issue: 5
Author(s): J.Y. Park, Y. Chang and G.H. Lee
Affiliation:
关键词: 癌症治疗,荧光成像-计算机断层扫描,钆中子俘获治疗,混合或纯镧系元素氧化物纳米颗粒,多模式成像,磁共振成像-计算机断层扫描,磁共振成像-计算机断层扫描-荧光成像,磁共振成像-荧光成像
摘要: Biomedical imaging is an essential tool for diagnosis and therapy of diseases such as cancers. It is likely true that medicine has developed with biomedical imaging methods. Sensitivity and resolution of biomedical imaging methods can be improved with imaging agents. Furthermore, it will be ideal if imaging agents could be also used as therapeutic agents. Therefore, one dose can be used for both diagnosis and therapy of diseases (i.e., theragnosis). This will simplify medical treatment of diseases, and will be also a benefit to patients. Mixed (Ln1xLn2yO3, x + y = 2) or unmixed (Ln2O3) lanthanide (Ln) oxide nanoparticles (Ln = Eu, Gd, Dy, Tb, Ho, Er) are potential multi-modal imaging and cancer therapeutic agents. The lanthanides have a variety of magnetic and optical properties, useful for magnetic resonance imaging (MRI) and fluorescent imaging (FI), respectively. They also highly attenuate X-ray beam, useful for X-ray computed tomography (CT). In addition gadolinium-157 (157Gd) has the highest thermal neutron capture cross section among stable radionuclides, useful for gadolinium neutron capture therapy (GdNCT). Therefore, mixed or unmixed lanthanide oxide nanoparticles can be used for multi-modal imaging methods (i.e., MRI-FI, MRI-CT, CT-FI, and MRICT- FI) and cancer therapy (i.e., GdNCT). Since mixed or unmixed lanthanide oxide nanoparticles are single-phase and solid-state, they can be easily synthesized, and are compact and robust, which will be beneficial to biomedical applications. In this review physical properties of the lanthanides, synthesis, characterizations, multi-modal imagings, and cancer therapy of mixed and unmixed lanthanide oxide nanoparticles are discussed.
Export Options
About this article
Cite this article as:
J.Y. Park, Y. Chang and G.H. Lee , Multi-Modal Imaging and Cancer Therapy Using Lanthanide Oxide Nanoparticles: Current Status and Perspectives, Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867322666141128162843
DOI https://dx.doi.org/10.2174/0929867322666141128162843 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Current Molecular Medicine Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery)
Current Pharmaceutical Design DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Editorial [Hot Topic: Target Therapy in Brain Tumours and Metastases (Guest Editors: M. Caraglia and R. Addeo)]
Current Cancer Drug Targets Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets New Strategy Developments in Brain Tumor Therapy
Current Pharmaceutical Design Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy
Current Pharmaceutical Design Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets